Keywords
peritonitis
intraperitoneal amikacine
How to Cite
Abstract
Peritonitis (P) is the main complication and primary limiting factor in the extension of continuous ambulatory peritoneal dialysis(CAPD) in developing countries, because of exposure to potential external contamination, especially in people with unsatisfactory hygiene habits. We will present a case of peritonitis in 62 years old woman after the first three months of CAPD treatment. The peritoneal infection is confirmed by a cloudy fluid with increased WBC in the dialysis solution (2300..1300..1100 cells/mm; polymorphonuclears between 60% to 80%), augmented fluid protein content(cca.2.4 g/l), presence of microorganisms and symptoms of acute peritoneal infection(isolated Enterobacteria species, abdominal pain and diarrhoea). The peritonitis was treated following the Oreopoulos group’s recommendations and after a report of the sensitivity of the isolated Enterobacteria, with an appropriate antibiotic (Amikacine) in recommended intraperitoneal dose. Three days after successful treatment of peritonitis, the definite deafness is developed.
References
2. Keane WF et al. CAPD peritonitis treatment recommendations-1989 update. 1989. Peritoneal Dialysis International. 9, 247-256.
3. Lamperi S, Carozzi S, Nasimi MG. Intraperitoneal immunoglobulin treatment in prophylaxis of bacterial peritonitis in CAPD. 1986. In Advence in CAPD (Eds R.Khanna et al. ) pp 110-113, Peritoneal Dialysis Bulletin, Inc Toronto
4. Lamperi S, Carozzi S .Immunological defences in CAPD. 1989. Blood Purification. 7, 126-146.
Submission of a manuscript implies that the submitted work has not been published before (except as part of a thesis or report, or abstract); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors. If and when the manuscript is accepted for publication, the author(s) still hold the copyright and retain publishing rights without restrictions. Authors or others are allowed to multiply article as long as not for commercial purposes. For the new invention, authors are suggested to manage its patent before published. The license type is (CC BY-NC 4.0)